U.S. Markets closed
  • S&P Futures

    4,284.75
    -56.75 (-1.31%)
     
  • Dow Futures

    33,674.00
    -381.00 (-1.12%)
     
  • Nasdaq Futures

    13,937.50
    -221.00 (-1.56%)
     
  • Russell 2000 Futures

    1,937.60
    -35.10 (-1.78%)
     
  • Crude Oil

    86.79
    -0.56 (-0.64%)
     
  • Gold

    1,815.10
    -14.60 (-0.80%)
     
  • Silver

    23.38
    -0.43 (-1.81%)
     
  • EUR/USD

    1.1226
    -0.0019 (-0.1684%)
     
  • 10-Yr Bond

    1.8480
    +0.0650 (+3.65%)
     
  • Vix

    31.96
    +0.80 (+2.57%)
     
  • GBP/USD

    1.3436
    -0.0026 (-0.1948%)
     
  • USD/JPY

    114.6570
    -0.0030 (-0.0026%)
     
  • BTC-USD

    35,738.05
    -1,637.53 (-4.38%)
     
  • CMC Crypto 200

    812.71
    -43.10 (-5.04%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    26,321.33
    -689.97 (-2.55%)
     

Vivos Therapeutics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • VVOS

Vivos management to present at 7:00 am EDT on September 13, 2021

HIGHLANDS RANCH, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring, today announced that Kirk Huntsman, Chief Executive Officer, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 am EDT on Monday, September 13, 2021.

If you are an institutional or retail investor, and would like to listen to the Company’s presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference. You may also listen to the company presentation online at:

https://journey.ct.events/view/31441d30-9dd0-4c62-b9d9-8ac7be21c128

A replay of the presentation will be available for view following the presentation on Vivos’ website at: https://vivoslife.com/investor-relations/

About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (OSA). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients treated worldwide by more than 1,250 trained dentists.

Combining proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology, for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.

For more information, visit www.vivoslife.com.

About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com

For more information and/or to register for the conference please visit: https://journey.ct.events/view/31441d30-9dd0-4c62-b9d9-8ac7be21c128

Cautionary Note Regarding Forward-Looking Statements
This press release, the presentation referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “aim”, “may”, “could”, “expects”, “projects,” “intends”, “plans”, “believes”, “predicts”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC's website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Investor Relations Contact:
Edward Loew
Investor Relations Officer
(602) 903-0095
ed@vivoslife.com

Media Relations Contact:
Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (917) 420-1444
ckasunich@kcsa.com / jrobles@kcsa.com